Northern Trust
MRNA icon

Northern Trust’s Moderna MRNA Stock Holding History

Northern Trust’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150M Sell
2,952,041
-50,537
-2% -$2.36M 0.02% 585
2025
Q4 		$88.5M Buy
3,002,578
+97,069
+3% +$2.64M 0.01% 790
2025
Q3 		$75M Sell
2,905,509
-184,772
-6% -$5.15M 0.01% 878
2025
Q2 		$85.3M Sell
3,090,281
-29,345
-0.9% -$773K 0.01% 789
2025
Q1 		$88.4M Buy
3,119,626
+160,572
+5% +$5.7M 0.01% 759
2024
Q4 		$123M Buy
2,959,054
+354,871
+14% +$17M 0.02% 627
2024
Q3 		$174M Sell
2,604,183
-235,084
-8% -$21.6M 0.03% 472
2024
Q2 		$337M Sell
2,839,267
-29,687
-1% -$3.76M 0.06% 291
2024
Q1 		$306M Sell
2,868,954
-103,042
-3% -$10.4M 0.05% 321
2023
Q4 		$296M Buy
2,971,996
+940
+0% +$79.1K 0.05% 328
2023
Q3 		$307M Buy
2,971,056
+55,177
+2% +$6.15M 0.06% 305
2023
Q2 		$354M Sell
2,915,879
-287,565
-9% -$38.4M 0.07% 280
2023
Q1 		$492M Sell
3,203,444
-67,114
-2% -$11.1M 0.1% 202
2022
Q4 		$587M Buy
3,270,558
+44,752
+1% +$7.32M 0.12% 169
2022
Q3 		$381M Sell
3,225,806
-121,782
-4% -$18.5M 0.09% 223
2022
Q2 		$478M Sell
3,347,588
-155,737
-4% -$22.3M 0.1% 189
2022
Q1 		$603M Buy
3,503,325
+20,416
+0.6% +$3.44M 0.11% 172
2021
Q4 		$885M Buy
3,482,909
+23,555
+0.7% +$6.89M 0.14% 128
2021
Q3 		$1.33B Buy
3,459,354
+1,510,266
+77% +$557M 0.24% 81
2021
Q2 		$458M Buy
1,949,088
+112,251
+6% +$20.1M 0.08% 224
2021
Q1 		$241M Buy
1,836,837
+11,466
+0.6% +$1.66M 0.04% 370
2020
Q4 		$191M Buy
1,825,371
+1,600
+0.1% +$162K 0.04% 425
2020
Q3 		$129M Sell
1,823,771
-5,590
-0.3% -$390K 0.03% 477
2020
Q2 		$117M Buy
1,829,361
+729,335
+66% +$39.9M 0.03% 490
2020
Q1 		$32.9M Buy
1,100,026
+129,361
+13% +$2.98M 0.01% 1052
2019
Q4 		$19M Buy
970,665
+39,242
+4% +$696K ﹤0.01% 1764
2019
Q3 		$14.8M Buy
931,423
+743,929
+397% +$11M ﹤0.01% 1891
2019
Q2 		$2.74M Buy
187,494
+138,031
+279% +$2.96M ﹤0.01% 2881
2019
Q1 		$1.01M Buy
+49,463
New +$918K ﹤0.01% 3355

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust's MRNA Position: Q1 2026 in Review

Northern Trust reduced its Moderna (MRNA) stake by 1.7% in Q1 2026, selling an estimated $2.36M and leaving 2,952,041 shares worth $150M. The position accounts for 0.02% of the portfolio, ranked #585.

Northern Trust first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.33B in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Northern Trust held 2,952,041 shares of Moderna worth $150M as of Q1 2026.
  • Northern Trust sold 50,537 Moderna shares in Q1 2026, an estimated $2.36M.
  • Moderna made up 0.02% of Northern Trust's portfolio in Q1 2026, its #585 holding.
  • Northern Trust first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Northern Trust's Moderna position peaked at $1.33B in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.